Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.57 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.57 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.57 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372465 | 0.86 | PLAAT3 (0.60) | KMT2AALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL17372518 | 0.84 | HPGD (0.57) | KMT2AALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL4079701 | 0.80 | SMN1; SMN2 (0.65) | KMT2AALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL13917987 | 0.80 | HDAC3 (0.66) | HPGDPLAAT5PLAAT4TRPV1 | |
| SCHEMBL17372428 | 0.79 | KMT2A (0.58) | KMT2AALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4034877 | 0.78 | ALDH1A1 (0.63) | KMT2AALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL4079697 | 0.78 | SMN1; SMN2 (0.75) | KMT2AALDH1A1SMN1; SMN2MEN1NPC1 | |
| SCHEMBL11863114 | 0.76 | SMN1; SMN2 (0.57) | KMT2AALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL5939993 | 0.76 | CHRM2 (0.63) | KMT2AALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL28992291 | 0.76 | ALDH1A1 (0.68) | KMT2AALDH1A1SMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154934-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE (FR) | 2021-04-14 | — | — | EP | claimed |
| US-20210040034-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE II DROIT & SANTE (FR) | 2021-02-11 | — | — | US | claimed |
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2020-11-24 | — | — | US | claimed |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-03-28 | — | — | US | claimed |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE (FR) | 2017-04-20 | — | — | US | claimed |
| EP-3154934-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | Université de Lille 2 Droit et Santé (FR) | 2017-04-19 | — | — | EP | claimed |
| WO-2015193255-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2015-12-23 | — | — | WO | claimed |
| EP-3154934-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE (FR) | 2021-04-14 | — | — | EP | disclosed |
| US-20210040034-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIV LILLE II DROIT & SANTE (FR) | 2021-02-11 | — | — | US | disclosed |
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2020-11-24 | — | — | US | disclosed |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-03-28 | — | — | US | disclosed |
| US-10179761-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-01-15 | — | — | US | disclosed |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE (FR) | 2017-04-20 | — | — | US | disclosed |
| EP-3154934-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | Université de Lille 2 Droit et Santé (FR) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015193255-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040034-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | KMT2A 4371/4885ALDH1A1 1189/4885SMN1; SMN2 13/4885 |
| US-10844008-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | MAPT, PSEN2, SNCA | KMT2A 4371/4885ALDH1A1 1189/4885SMN1; SMN2 13/4885 |
| US-20170107174-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | KMT2A 4371/4885ALDH1A1 1189/4885SMN1; SMN2 13/4885 |
| US-20190092721-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES | MAPT, PSEN2, SNCA | KMT2A 4371/4885ALDH1A1 1189/4885SMN1; SMN2 13/4885 |
| US-10179761-B2 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | MAPT, PSEN2, SNCA | KMT2A 4371/4885ALDH1A1 1189/4885SMN1; SMN2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.